Cited by 658Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Open access

Green, Robert C.·2009·JAMA

DOI 10.1001/jama.2009.1866PMC PMC2902875

Open this paper in CoChat — free account

Abstract

CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted. INTERVENTION: Tarenflurbil, 800 mg, or placebo, administered twice a day. MAIN OUTCOME MEASURES: Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. RESULTS: Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. CONCLUSION: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00105547.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2009.1866

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,851
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,006
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 658

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 131
Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications
Wang, J., Bi, W., Cheng, A., Freire, D., Vempati, P., Zhao, W., Gong, B., Janle, E. M., Chen, T., Ferruzzi, M. G., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00042 · Cited by 128
Alzheimer's disease failed clinical trials
Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 130
Amyloid-β Peptide: Dr. Jekyll or Mr. Hyde?
Puzzo, D., & Arancio, O. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129033 · Cited by 134
Pharmacological Treatment of Alzheimer Disease
Massoud, F., & Léger, G. C. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601003 · Cited by 130
Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
De Strooper, B., & Chávez Gutiérrez, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124309 · Cited by 119
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis’ still alive?
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119
EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques
Kim, H. Y., Kim, H. V., Jo, S., Lee, C. J., Choi, S. Y., Kim, D. J., & Kim, Y. S. (2015) · Nature Communications · doi:10.1038/ncomms9997 · Cited by 122
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 119
A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment
Morimoto, B. H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., & on behalf of the AL-108-211 Study Investigators (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000348347 · Cited by 115
Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease
Sharma, V., Kaur, A., & Singh, T. G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110373 · Cited by 116
Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1
Ohki, Y., Higo, T., Uemura, K., Shimada, N., Osawa, S., Berezovska, O., Yokoshima, S., Fukuyama, T., Tomita, T., & Iwatsubo, T. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.372 · Cited by 113
Precision pharmacology for Alzheimer’s disease
Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114
Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT)
The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.012 · Cited by 115
Novel insights for the treatment of Alzheimer's disease
Kurz, A., & Perneczky, R. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.018 · Cited by 115
Quantitative sodium MR imaging: A review of its evolving role in medicine
Thulborn, K. R. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.11.056 · Cited by 116
Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's Disease
Reitz, C., Tosto, G., Mayeux, R. P., Luchsinger, J. A., & the NIA-LOAD/NCRAD Family Study Group and the Alzheimer's Disease Neuroimaging Initiative (2012) · PLoS ONE · doi:10.1371/journal.pone.0050354 · Cited by 109
Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty
Kimmelman, J., & London, A. J. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001010 · Cited by 109
Natural Products As A Rich Source Of Tau-Targeting Drugs For Alzheimer’s Disease
Calcul, L., Zhang, B., Jinwal, U. K., Dickey, C. A., & Baker, B. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.124 · Cited by 108
Rho GTPases as therapeutic targets in Alzheimer’s disease
Aguilar, B. J., Zhu, Y., & Lu, Q. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0320-4 · Cited by 110
Purinergic receptors as potential therapeutic targets in Alzheimer's disease
Woods, L. T., Ajit, D., Camden, J. M., Erb, L., & Weisman, G. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.031 · Cited by 109
Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials
Kang, J. M., Yeon, B. K., Cho, S., & Suh, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160406 · Cited by 106
Highly Selective Butyrylcholinesterase Inhibitors With Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer’s Disease Mouse Model
Hoffmann, M., Stiller, C., Endres, E., Scheiner, M., Gunesch, S., Sotriffer, C., Maurice, T., & Decker, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01012 · Cited by 105
Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells
Coronel, R., Bernabeu-Zornoza, A., Palmer, C., Moreno, M. D. M. M., Zambrano, A., Cano, E., & Liste, I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0914-2 · Cited by 112
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology
Giuffrida, M. L., Caraci, F., Bona, P. D., Pappalardo, G., Nicoletti, F., Rizzarelli, E., & Copani, A. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.2.83 · Cited by 94
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation
Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 90
Emerging Therapeutics for Alzheimer's Disease
Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 95
Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease
Satlin, A., Wang, J., Logovinsky, V., Berry, S. M., Swanson, C. J., Dhadda, S., & Berry, D. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z. K., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 87
Multi-target drugs for Alzheimer's disease
Turgutalp, B., & Kızıl, Ç. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.05.005 · Cited by 87
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders
Sim, T. M., Dinesh, T., Dheen, S. T., Bay, B., & Srinivasan, D. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176070 · Cited by 84
γ-Secretase as a Target for Alzheimer’s Disease
Wolfe, M. S. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00004-0 · Cited by 85
Proteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 84
Predictors of long-term cognitive outcome in Alzheimer's disease
Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt85 · Cited by 81
Mild versus moderate stages of Alzheimer’s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 83
Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials
Jia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 84
Potential role of antimicrobial peptides in the early onset of Alzheimer's disease
Welling, M. M., Nabuurs, R. J. A., & van der Weerd, L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.020 · Cited by 81
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 85
Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease
Wong, L. R., & Ho, P. C. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12836 · Cited by 79
Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.027 · Cited by 80
Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment
Clark, D. G., McLaughlin, P. M., Woo, E., Hwang, K., Hurtz, S., Ramirez, L. M., Eastman, J. A., Dukes, R., Kapur, P., DeRamus, T. P., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.001 · Cited by 82
Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer’s Disease
Sikanyika, N. L., Parkington, H. C., Smith, A. I., & Kuruppu, S. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02756-x · Cited by 79
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
The pattern of atrophy in familial Alzheimer disease
Cash, D. M., Ridgway, G. R., Liang, Y., Ryan, N. S., Kinnunen, K. M., Yeatman, T., Malone, I. B., Benzinger, T. L. S., Jack, C. R., Thompson, P. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a841c6 · Cited by 80
Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
Rogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
The Diarylheptanoid (+)-aR,11S-Myricanol and Two Flavones from Bayberry (Myrica cerifera) Destabilize the Microtubule-Associated Protein Tau
Jones, J. R., Lebar, M. D., Jinwal, U. K., Abisambra, J. F., Koren, J., Blair, L. J., O’Leary, J. C., Davey, Z. S., Trotter, J. H., Johnson, A. G., et al. (2010) · Journal of Natural Products · doi:10.1021/np100572z · Cited by 78
Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales
Clark, I. A., Atwood, C., Bowen, R. L., Paz-Filho, G., & Vissel, B. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005850 · Cited by 76
The intestinal microbiome and Alzheimer's disease: A review
Li, Z., Zhu, H., Zhang, L., & Qin, C. (2018) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12033 · Cited by 78
Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice
Oster, T., & Pillot, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.011 · Cited by 74
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD)
Lukiw, W. J. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.672559 · Cited by 76
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 75
Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74
Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer’s Disease Patients
Ribarič, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063245 · Cited by 77
Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
van Norden, A. G. W., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olde-Rikkert, M. G. M., & de Leeuw, F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.003 · Cited by 75
Difunctional Cu-doped carbon dots: catalytic activity and fluorescence indication for the reduction reaction of p-nitrophenol
Du, J., Zhao, Y., Chen, J., Zhang, P., Gao, L., Wang, M., Cao, C., Wen, W., & Zhu, C. (2017) · RSC Advances · doi:10.1039/c7ra05383e · Cited by 70
Phytotherapy: A promising approach for the treatment of Alzheimer's disease
John, O. O., Amarachi, I. S., Chinazom, A. P., Adaeze, E., Kale, M. B., Umare, M. D., & Upaganlawar, A. B. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100030 · Cited by 69
Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer's Disease-related Biomarker in 5XFAD Mice
Xiao, N., Zhang, J., Zhou, M., Wei, Z., Wu, X., Dai, X., Zhu, Y., & Chen, X. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.162507 · Cited by 69
Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model
Meister, S., Zlatev, I., Stäb, J., Docter, D., Baches, S., Stauber, R. H., Deutsch, M., Schmidt, R., Ropele, S., Windisch, M., et al. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt225 · Cited by 73
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 69
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 70
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 68
Multi-target-directed triazole derivatives as promising agents for the treatment of Alzheimer’s disease
Kaur, A., Mann, S., Kaur, A., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.058 · Cited by 66
Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies
Broadstock, M., Ballard, C. G., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 68
Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease
Wilson, B., & Geetha, K. M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.044 · Cited by 67
High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines
Cummings, J. L., Geldmacher, D., Farlow, M. R., Sabbagh, M. N., Christensen, D. D., & Betz, P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12076 · Cited by 64
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63
Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review
Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 66
Hypoxia-Induced Neuroinflammation in Alzheimer’s Disease: Potential Neuroprotective Effects of Centella asiatica
Hambali, A., Kumar, J., Hashim, N. F. M., Maniam, S., Mehat, M. Z., Cheema, M. S., Mustapha, M., Adenan, M. I., Stanslas, J., & Hamid, H. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.712317 · Cited by 65
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 66
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
New Therapeutic Targets in Alzheimer's Disease
Coman, H. G., & Nemeş, B. (2017) · International journal of gerontology · doi:10.1016/j.ijge.2016.07.003 · Cited by 63
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
Targets for AD treatment: conflicting messages from γ-secretase inhibitors
Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell, E., Sharma, E., Mazell, C., Bhat, N. R., Kindy, M. S., Lahiri, D. K., & Pappolla, M. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07213.x · Cited by 62
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea racemosa
Findeis, M. A., Schroeder, F. C., McKee, T. D., Yager, D., Fraering, P. C., Creaser, S. P., Austin, W., Clardy, J., Wang, R., Selkoe, D. J., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000857 · Cited by 61
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi‐Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 63
Glymphatic system dysfunction in neurodegenerative diseases
Beschörner, N., & Nedergaard, M. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001252 · Cited by 60
Novel Huprine Derivatives with Inhibitory Activity toward β‐Amyloid Aggregation and Formation as Disease‐Modifying Anti‐Alzheimer Drug Candidates
Viayna, E., Gómez, T., Galdeano, C., Ramírez, L., Ratia, M., Badı́a, A., Clos, M. V., Verdaguer, E., Junyent, F., Camins, A., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.201000322 · Cited by 63
APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation
Mertens, J., Stüber, K., Wunderlich, P., Ladewig, J., Kesavan, J., Vandenberghe, R. R., Vandenbulcke, M., Damme, P. V., Walter, J., Brüstle, O., et al. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.10.011 · Cited by 60
Concise Review: Can Stem Cells be Used to Treat or Model Alzheimer's Disease?
Chen, W. W., & Blurton-Jones, M. M. (2012) · Stem Cells · doi:10.1002/stem.1240 · Cited by 62
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 65
Turning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
Dysken, M. W., Guarino, P., Vertrees, J. E., Asthana, S., Sano, M. C., Llorente, M. D., Pallaki, M., Love, S. B., Schellenberg, G. D., McCarten, J. R., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.014 · Cited by 62
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Microbiota-gut-brain axis and Alzheimer’s disease: Implications of the blood-brain barrier as an intervention target
Liu, S., Gao, J., Liu, K., & Zhang, H. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111560 · Cited by 59
Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 59
Alzheimers Disease: Pathological Mechanisms and Recent Insights
Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 62
Review: Experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57
Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease
Broeck, B. V., Chen, J., Tréton, G., Desmidt, M., Hopf, C., Ramsden, N. G., Karran, E. H., Mercken, M. H., & Rowley, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01207.x · Cited by 59
Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets
Gross, A. L., Sherva, R., Mukherjee, S., Newhouse, S., Kauwe, J. S. K., Munsie, L. M., Waterston, L. B., Bennett, D. A., Jones, R. N., Green, R. C., et al. (2014) · Neuroepidemiology · doi:10.1159/000367970 · Cited by 57
Self-citation
γ-Secretase and the Intramembrane Proteolysis of Notch
Jorissen, E., & Strooper, B. D. (2010) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92006-1 · Cited by 61
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 59

Authors: Green, R. C.
Affiliations: Boston University (US)
Corresponding author: Green, Robert C.
ORCID: Green, Robert C.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2009-12-16
Volume: 302
Issue: 23
Pages: 2557
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2009.1866
PMC: PMC2902875
OpenAlex: W1982816514
Cited by: 643
References: 44
Citations by year: 2026: 11 · 2025: 25 · 2024: 39 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 43 · 2019: 32 · 2018: 26 · 2017: 40 · 2016: 40 · 2015: 31 · 2014: 44 · 2013: 52 · 2012: 63
FWCI: 38.79
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Pennsylvania
National Institute for Health and Care Research
National Institutes of Health (RR00533, HG02213, AG13846)
National Institute on Aging (P30AG008051, K24AG027841, P50AG005142, P30AG013846, P30-AG13846))
National Human Genome Research Institute (R01HG002213, R01 HG02213)
National Center for Research Resources (M01-RR-00533, M01RR000533)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, mild Alzheimer disease, cognitive decline, activities of daily living, disease modification, ADAS-Cog, drug safety and efficacy, dizziness, anemia, infection
MeSH terms: Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognition Disorders, Double-Blind Method, Enzyme Inhibitors, Female, Flurbiprofen, Humans, Male, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks